logo
  Join        Login             Stock Quote

Notable Calls this Morning: Novellus Systems, Amag Pharma

 April 09, 2008 09:47 AM
 


Novellus Systems (NASDAQ:NVLS): Upgraded to Buy at Amtech

AmTech: Novellus Systems (NASDAQ:NVLS): upgrade to Buy. We think much of yesterday's neg pre-ann was based on 1-time events including CMP rev recognition change, inventory write-down, & higher tax rate. Based on checks we think a restructuring of NVLS's biz is currently underway and CMP and dry strip will be discontinued (unprofitable), along w/layoffs. This will improve NVLS's profitability & make it more attractive as a take-over candidate. Stock is currently trading near trough valn levels at 1.6x book. PT $27.50.

Notablecalls: I like this call as the timing is just perfect. The stock got killed yesterday following the pre-announcement & looks to be ready for a bounce.

Strongly believe Ferumoxytol will recieve first pass approval- Jefferies

Jefferies out on the box saying to buy AMAG agressively here. Analyst says there will be NO delay.

Notablecalls: I do agree - at $38 the stock is a buy.

Deets: Jefferies notes on Friday they held a conference call for clients featuring AMAG CEO Dr. Brian Pereira. The firm says AMAG bears have argued that the ferumoxytol development program does not include a sufficient number of patient exposures to meet I.C.H safety guidelines (N=1,500). To set the record straight the firm notes, AMAG's CEO went on record (again) to confirm that, in total, over 1,700 patients and healthy volunteers were treated with ferumoxytol in the co's eleven clinical studies. The firm also says the fact that AMAG has the resources to execute additional clinical trials in C.K.D, but has chosen not to do so, suggests that AMAG strongly believes the filing is complete in its current form, per FDA guidance.

Downgraded to Sell at Merrill Lynch

Merrill saying it's worth $21 to $29. They now see potential for a delayed launch til 2011.
This thing could be down 10%+ today.


PS: One NCN member has some interesting comments on the AMAG downgrade.
It's the third time hes downgraded it in 10 weeks - first Jan 30 then Feb 28 and now. Nothing new in the report. Also the analyst was hired by Merrill only last year and I think the guy's trying to make a name for himself.

Jan 30 he went from a $100 target to $78 the stock fell 6 points. Than Feb 28 he went to Neutral and stock fell $4 I think.

I'm just saying the whole street knows he has it out for AMAG.

Notablecalls: Excellent colour.
iOnTheMarket Premium
Advertisement

Advertisement


Comments Closed


rss feed

Latest Stories

article imageChipotle Mexican Grill, Inc. (CMG) Q2 Earnings Preview: Will Higher Traffic Offset Higher Costs the Key

Chipotle Mexican Grill, Inc. (NYSE:CMG) will host a conference call to discuss second quarter 2014 read on...

article imageNetflix, Inc. (NFLX) Q2 Earnings Preview: The Ruby Month for a Reason

Netflix, Inc. (NASDAQ:NFLX) will post its second-quarter 2014 financial results and business outlook on its read on...

article imageLadenburg Thalmann Financial Services (NYSEMKT:LTS): Heavy, Durable Insider Buying

Ahh, but any worries over price levels didn’t stop multiple insiders at Ladenburg Thalmann Financial read on...

article imageInternational Business Machines Corp. (IBM) Q2 Earnings Preview: Small Beat and Pop

International Business Machines Corp. (NYSE:IBM) will host a conference call Wednesday, Jul. 16, 2014 at read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.